Option chain shows key data for ProMIS Neurosciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for ProMIS Neurosciences.

ProMIS Neurosciences (NASDAQ:PMN) Stock, Option Chain

ProMIS Neurosciences

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Crypto,Trader,Investor,Broker,Using,Smartphone,App,Analyzing,Financial,Data

News

Initiation

Markets

Analyst Ratings

Trading Ideas

FRST

NRSN

This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday

Penny,Stock,Investments,Taking,Off,Concept

Penny Stocks

EMMA

ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying

Chi sale e chi scende: i maggiori movimenti nel pre-market di oggi

Pre-Market Outlook

Movers

ALLR

EFSH

FRGT

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MYNA

OMEX

PGNY

SGLY

SMSI

TBIO

VEEA

VERO

WBUY

XCUR

Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket

ProMIS Neurosciences Inc. - Common Shares

ProMIS Neurosciences Inc

Perfect Moment Ltd

PERSEUS MINING LTD ORD by Perseus Mining Ltd

Perseus Mining Ltd

Press Releases

ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer's Disease

ProMIS Neurosciences Issues Letter to Shareholders

Biotech

General

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Maxim Group

Guggenheim

BTIG

Comments

ProMIS Neurosciences

ProMIS Neurosciences (PMN) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell